COVID-19 Biobank

Supporting Researchers Working on the Novel Virus

 

The COVID-19 Biobank will initially be collecting specimens from inpatients who have tested positive or are showing signs consistent with COVID-19.

Request specimens from the bank through the CCTS Service Request Formselect "Biospecimens" and then select the "COVID19 Biobank".

COVID-19 illustration

The CCTS has partnered with many areas across the UK to develop a COVID-19 Biobank. Partners include,  but are not limited to, Markey Cancer Center, UKHC Clinical Laboratory, the Department of Internal Medicine, Divisions of Infectious Disease and Pulmonary, Critical Care and Sleep Medicine, and many faculty members.

 

 

The informed consent process for the COVID-19 Biobank is handled remotely via Redcap. This video provides instructions for the remote consent process. 

 

 

 

 

Information about the general CCTS Biobank is available here

 

In the News
Title Card for "The Rebound Kentucky: Relieve, Respond, Revive

The CCTS COVID-19 Biobank was recently featured on LEX18's Rebound Kentucky series. 

COVID-19 Biobank Team

COVID-19 News from the CCTS

  • LEX18 Covid-19 Blood Clot Story
    • Oct 16 2020

    The research, supported by a COVID-19 pilot grant from the CCTS, suggests lung damage caused by COVID-19 might be to blame for prolonged clot risk.

  • Behind the Blue logo
    • Oct 13 2020

    Dr. Lisa Cassis, UK’s vice president for research, oversees the university’s vast medical and nonmedical research efforts. On this episode of "Behind the Blue," she discusses the many areas UK's Office of Research is prioritizing, including greater diversity and inclusion, the increasing commitment to opportunities for undergraduate research, returning research efforts to higher capacity during the COVID-19 pandemic, and more.

  • UK researcher Jeremy Wood, pictured in his lab wearing a white coat, is co-leading research that may provide answers for why so many COVID-19 patients experience blood clotting.
    • Sep 17 2020

    The study suggests that localized inflammation in the lungs caused by COVID-19 may be responsible for the increased presence of blood clots in patients, and that the risk of thrombosis could persist after the infection clears.